At Evidence EU 2014, Tara Symonds , Senior Director, Pfizer, gave a presentation on “How can patient reported outcomes generate evidence to validate health claims?”
Symonds’ presentation reveals her belief that PRO data is increasingly seen as important by payers for validating health claims from a patient perspective. She also mentions both the EU HTA community and US Federal government calling for more relative/comparative research to reimburse drugs. PRO data will, therefore, be seen as important in such studies.
Download and Learn:
Why are PRO’s important to measure?
Generating PRO’s value messages
PRO measurement in the drug development process
Found this interesting? Join us at Evidence EU 2015, happening 24-26 Feb 2015. Now in its second year and has established itself as one of the largest gatherings of observational research leaders in the world. Find out more